Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indaptus Therapeutics, Inc. (Nasdaq: INDP) SEC filings page on Stock Titan provides structured access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology issuer incorporated in Delaware and listed on the Nasdaq Capital Market, Indaptus uses its SEC reports to describe the development of its Decoy bacterial immunotherapy platform, its clinical programs, and its financing and corporate activities.
Through Forms 10-K and 10-Q, investors can review detailed discussions of Indaptus’ business, including its focus on Decoy20 and related product candidates for cancer and viral infections, pre-clinical data summaries, risk factors, and management’s analysis of research and development and general and administrative expenses. Current reports on Form 8-K capture material events such as the launch and progression of the INDP-D101 clinical trial, reverse stock split implementation, private placements of convertible promissory notes and warrants, standby equity purchase agreements, preferred stock financings, and changes to the board of directors and executive leadership.
Registration statements on Form S-1 and amendments (S-1/A) outline the terms of securities offerings, including common stock, pre-funded warrants, common warrants and placement agent warrants, as well as estimated offering expenses and recent sales of unregistered securities. These filings also confirm Indaptus’ status as a smaller reporting company and non-accelerated filer and provide information on its incorporation and principal executive offices.
On Stock Titan, users can access these filings alongside AI-powered summaries that highlight key points such as capital structure changes, potential dilution from convertible instruments and warrants, and the implications of preferred stock transactions. The platform also surfaces insider-related disclosures and board changes reported in 8-Ks, helping readers quickly identify governance developments. Real-time updates from EDGAR ensure that new Indaptus filings, from quarterly earnings reports to material event disclosures, are added promptly, while AI-generated explanations help interpret complex prospectus language, financing terms and clinical program descriptions within the filings.
Indaptus Therapeutics, Inc. received an ownership update from several large investors who amended their beneficial holdings and clarified their relationship. As of March 31, 2026, Yun Yao reports beneficial ownership of 41,991,000 shares of common stock, or 37.1% of the company. Sino Lion Ventures Limited and its controlling person, Chenhao Xu, each report 38,895,000 shares, representing 34.3% of the common stock. Junyi Dai and Ting Yang each report 11,250,000 shares, or 9.9%, while Lina Deng reports 5,550,000 shares, or 4.9%. All shares were issued upon conversion of Series AA and Series AAA Preferred Stock under a Securities Purchase Agreement that closed on March 23, 2026. The amendment states that the reporting persons have disbanded any group that may have existed under that agreement and will no longer act as a group, and it serves as an exit filing for Lina Deng, who fell below five percent ownership due to an increase in shares outstanding to 113,242,324.
Indaptus Therapeutics, Inc. filed an amended current report to update a director’s legal name to Johnny Fox Arrowsmith, previously disclosed as Yí Zhang. The amendment also restates recent board changes.
On April 17, 2026, the board appointed Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors, effective April 22, 2026. Both entered into independent director and indemnification agreements. Each will receive an annual cash retainer of $30,000, payable quarterly, plus reimbursement of reasonable expenses. The board determined both are independent under Nasdaq listing standards.
The board is divided into three classes. Mr. Ruan and Dr. Arrowsmith were appointed as Class II directors with terms expiring at the 2026 annual stockholders’ meeting. Junyi Dai and Qinglai Lu serve as Class III directors with terms expiring at the 2027 annual meeting.
Mr. Ruan was named to the audit committee and qualifies as an “audit committee financial expert.” Dr. Arrowsmith joined the nominating committee. The company states there are no family relationships or related-party transactions requiring disclosure for either director.
On April 22, 2026, director Matthew McMurdo resigned from the board. The company reports his resignation did not result from any disagreement regarding operations, policies, or practices.
Indaptus Therapeutics announced several board changes. The Board appointed Tim Ruan and Dr. Yi Zhang as independent Class II directors, effective April 22, 2026, with terms expiring at the 2026 annual stockholder meeting. Both bring capital markets, biotechnology, intellectual property, and life sciences expertise.
Each new director will receive an annual cash retainer of $30,000, payable quarterly, plus reimbursement of reasonable expenses, under Independent Director Agreements. They also entered Indemnification Agreements under Delaware law. Tim Ruan joins the Audit Committee and is designated an “audit committee financial expert,” while Dr. Zhang joins the Nominating Committee.
On April 22, 2026, director Matthew McMurdo resigned from the Board, and his resignation was stated not to result from any disagreement regarding operations, policies, or practices. The Board remains classified into three staggered classes, with Class II and Class III terms expiring in 2026 and 2027, respectively.
Indaptus Therapeutics, Inc. director Lu Qinglai filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists no transactions and shows no reported purchases, sales, or derivative exercises by the reporting person in the data provided.
Indaptus Therapeutics, Inc. — Amendment No. 1 to a Schedule 13G/A filed by YA II PN, Ltd. states that the reporting group beneficially owns 0 shares of Common Stock, representing 0% of the class as of 12/31/2025. The filing lists affiliated entities (YA Global Investments II (U.S.), Yorkville Advisors Global, YAII GP entities, SC-Sigma, and Mark Angelo) and explains their relationships and potential attribution. The amendment is signed and dated 04/06/2026.
Indaptus Therapeutics, Inc. reported leadership and board changes. Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and the company stated his resignation was not due to any disagreement regarding operations, policies, or practices.
On March 31, 2026, the board appointed Qinglai Lu, 48, as a director effective April 8, 2026 and determined he qualifies as an independent director under Nasdaq rules. The board also appointed Yu Ding, 51, as Chief Financial Officer effective April 1, 2026 after reviewing his qualifications.
The company adjusted its audit committee, with Matthew McMurdo resigning and Qinglai Lu and Jerome Jabbour joining the committee on March 31, 2026.
Indaptus Therapeutics, Inc. reported that investor Yun Yao is a more than 10% owner with 41,991,000 shares of common stock. These shares arose from a securities purchase agreement under which Yao acquired Series AA and Series AAA Convertible Non-Redeemable Preferred Stock and then converted all of it into common shares following the closing on March 23, 2026.
SINO LION VENTURES Ltd has become a major shareholder of Indaptus Therapeutics, Inc. by converting preferred stock into common shares. On March 19, 2026, it agreed to acquire 259,300 shares of Series AAA Convertible Non-Redeemable Preferred Stock from David Elliot Lazar. Each preferred share is convertible into 150 shares of common stock. After the transaction closed on March 23, 2026, SINO LION VENTURES Ltd submitted a notice of conversion for all of its Series AAA Preferred Stock, resulting in the issuance of 38,895,000 shares of common stock, which it now holds directly as reported on this initial Form 3. A footnote states these securities may also be deemed beneficially owned by Chenhao Xu, who disclaims beneficial ownership except for any pecuniary interest.
Indaptus Therapeutics Chief Executive Officer Junyi Dai reported ownership of 11,250,000 shares of common stock. This position reflects the full conversion of 75,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock, which were acquired under a securities purchase agreement and then immediately converted after closing.
Indaptus Therapeutics, Inc. (INDP) disclosed a new investor group led by Yun Yao acquiring and converting preferred stock into a large common equity position. The group bought Series AA and Series AAA Preferred Stock for an aggregate $11,200,000 under a Securities Purchase Agreement signed on March 19, 2026.
Following conversion on March 24, 2026, Yun Yao beneficially owns 41,991,000 common shares, or 37.8% of the class, Sino Lion Ventures Limited and its controller Chenhao Xu each report 38,895,000 shares, or 35.0% each, while Junyi Dai and Ting Yang each hold 11,250,000 shares, or 10.1%, and Lina Deng holds 5,550,000 shares, or 5.0%. All percentages are based on 111,178,324 common shares outstanding as of March 30, 2026, after giving effect to the conversion.
The filing notes the Reporting Persons may be deemed a “group” solely for purposes of the Purchase Agreement and related transactions, and they collectively may be deemed to share beneficial ownership of 108,936,000 common shares, while each disclaims beneficial ownership of others’ shares beyond their pecuniary interest. In connection with the closing on March 23, 2026, Junyi Dai was appointed Chief Executive Officer and a director, signaling an aligned management and ownership shift.